Amgen analysis shows benefit of Repatha in high risk patients
Amgen announced a new analysis from the Repatha cardiovascular outcomes FOURIER study that evaluates the effectiveness of Repatha in patients who have suffered a recent myocardial infarction, or MI. The analysis showed that patients who experienced a recent MI were at higher risk of subsequent cardiovascular, or CV, events compared to patients who had an MI over a year ago. In the analysis, the risk reduction for experiencing a heart attack, stroke or CV death, in Repatha-treated patients treated within one year post MI was 25% compared to 15% in those patients with a more distant MI. The results will be presented at the American Heart Association Annual Scientific Sessions in Philadelphia on Monday, November 18.